Log In
BCIQ
Print this Print this
 

RG7802

  Manage Alerts
Collapse Summary General Information
Company Roche
DescriptionBispecific antibody targeting carcinoembryonic antigen (CEA) and the CD3 receptor
Molecular Target Carcinoembryonic antigen (CEA) ; CD3
Mechanism of ActionBispecific antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat CEA expressing solid tumors
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today